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Background: The canine transmissible venereal tumour (CTVT) is a contagious cancer that is naturally transmitted
between dogs by the allogeneic transfer of living cancer cells during coitus. CTVT first arose several thousand years
ago and has been reported in dog populations worldwide; however, its precise distribution patterns and
prevalence remain unclear.
Results: We analysed historical literature and obtained CTVT prevalence information from 645 veterinarians and
animal health workers in 109 countries in order to estimate CTVT’s former and current global distribution and
prevalence. This analysis confirmed that CTVT is endemic in at least 90 countries worldwide across all inhabited
continents. CTVT is estimated to be present at a prevalence of one percent or more in dogs in at least 13 countries
in South and Central America as well as in at least 11 countries in Africa and 8 countries in Asia. In the United
States and Australia, CTVT was reported to be endemic only in remote indigenous communities. Comparison of
current and historical reports of CTVT indicated that its prevalence has declined in Northern Europe, possibly due to
changes in dog control laws during the nineteenth and twentieth centuries. Analysis of factors influencing CTVT
prevalence showed that presence of free-roaming dogs was associated with increased CTVT prevalence, while dog
spaying and neutering were associated with reduced CTVT prevalence. Our analysis indicated no gender bias for
CTVT and we found no evidence that animals with CTVT frequently harbour concurrent infectious diseases. Vincristine
was widely reported to be the most effective therapy for CTVT.
Conclusions: Our results provide a survey of the current global distribution of CTVT, confirming that CTVT is endemic
in at least 90 countries worldwide. Additionally, our analysis highlights factors that continue to modify CTVT’s
prevalence around the world and implicates free-roaming dogs as a reservoir for the disease. Our analysis also
documents the disappearance of the disease from the United Kingdom during the twentieth century, which appears
to have been an unintentional result of the introduction of dog control policies.
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The canine transmissible venereal tumour (CTVT) is a
naturally occurring transmissible cancer which is spread
between dogs by the allogeneic transfer of living cancer
cells. The disease is usually transmitted during coitus
[1-6] and results in the appearance of tumours most
often associated with the external genitalia of male and
female dogs (Figure 1). CTVT has been reported in
many countries around the world (reviewed in [7-12])
and is, to our knowledge, the oldest and most prolific
mammalian somatic cell lineage [13-15].* Correspondence: as2112@cam.ac.uk; epm27@cam.ac.uk
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article, unless otherwise stated.Genetic evidence suggests that CTVT first arose from
the somatic cells of an individual dog that lived several
thousand years ago [13-15]. Despite its ancient origin,
global populations of CTVT diverged only within the
last few hundred years [13-15], suggesting that CTVT
spread around the globe relatively recently. Despite nu-
merous historical and contemporary reports of the dis-
ease (reviewed in [7-12,16]), no systematic study of
CTVT’s distribution and prevalence has been performed.
Estimating the worldwide distribution and prevalence of
a common animal pathogen such as CTVT is a challen-
ging task [17-22]; in most countries the disease is not
considered notifiable, and in many areas animals do not
have access to veterinary care. Veterinary records areed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Canine transmissible venereal tumour (CTVT). CTVT affecting (A) a male dog (B) a female dog.
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prevalence may exist within countries due to seasonal,
demographic or geographic factors. Here, we used a
crowdsourcing approach to estimate CTVT’s distribu-
tion and prevalence by using the internet to contact and
source local CTVT prevalence estimates from 645 veter-
inarians and animal health workers worldwide. We show
that the disease’s prevalence is linked to national devel-
opment status and that dog management policies leading
to declines in the population of free-roaming dogs may
have caused its recent eradication from the United King-
dom. Further insight into the epidemiology of CTVT
may help elucidate the timing, route and manner of the
disease’s global spread. In addition, an understanding of
the factors influencing CTVT distribution and preva-
lence may inform policy decisions for CTVT control.Results
Historical worldwide CTVT distribution
We initially analysed the published literature in order to
understand the historical distribution of CTVT. We
found 317 reports of primary naturally occurring CTVT
cases in the published literature (see Additional file 1),
including case reports, experimental reports and retro-
spective studies. These records provide evidence of
CTVT on all six inhabited continents and range in date
from 1810 until the present time (see Additional file 1
and Additional file 2). The earliest known record of
CTVT is from London in 1810, where it was noted as
one of only two cancers known to afflict dogs [23]. We
found evidence that CTVT was present prior to 1910 in
the United States [24,25], France [26], Germany [27-33],
Italy [34], the United Kingdom [2,4,6,35-37], Japan [38]
and Papua New Guinea [39]. A 1906 report from Papua
New Guinea stated that CTVT was “endemic before the
advent of the white man” [39]. Two reports published in
the 1950s noted declines in CTVT prevalence, stating
that CTVT occurs “less commonly in London dogs”
(1954) [40] and that there has been a “reduction in inci-
dence” of CTVT in New York City (1951) [41]. Indeed,
our literature review documented a clear decline inCTVT in the United Kingdom during the twentieth cen-
tury (see Additional file 3).
Eighteen of the published reports provided a numerical
value for the prevalence of naturally occurring CTVT in
their study (see Additional file 4). The reported prevalence
of CTVT in affected populations ranged from 1% or less
(Jamaica, 1968 [42]; Kenya, 1972 [43]; Bangladesh, 2010
[44]) to almost 20% (Papua New Guinea, 1985 [45] and
1986 [46]; Mexico 2007 [47] and 2010 [48]).Current worldwide CTVT distribution
We designed and distributed an internet-based question-
naire with 18 predominantly multiple choice questions
regarding CTVT prevalence, features of CTVT-infected
dogs and conditions of local dog populations to more
than one thousand veterinarians and animal health
workers in 164 countries (full questionnaire is available
in Additional file 5). Respondents were asked to estimate
the prevalence of CTVT in their local area. We received
a total of 645 completed questionnaires from 109
countries.
The average estimated CTVT prevalence reported for
each country from which a minimum of three responses
were received is displayed in Figure 2A (see also Additional
file 6). In addition, a separate map displays each individual
respondent’s estimate of CTVT prevalence (see Additional
file 7). The data indicate that CTVT is estimated to occur
at between one and ten percent prevalence in dogs in most
countries in South and Central America as well as in parts
of Africa and Asia. The average reported prevalence by
continent is shown in Figure 2B. The highest estimated
CTVT prevalence that we recorded was in Belize, where
the average CTVT prevalence (calculated from 6 re-
sponses) was estimated to be between 10 and 20 percent.
Several countries (Canada, the Czech Republic, Finland,
the Netherlands, New Zealand, Sweden, Switzerland and
the United Kingdom) were consistently reported by all re-
spondents from that country to be free of endemic CTVT;
in these countries, the only CTVT cases were specifically
reported to be imported from abroad (see also Figure 2A
and Additional file 7). CTVT was reported as absent from
Figure 2 Worldwide CTVT distribution and prevalence. (A) CTVT worldwide distribution by country. The colour of each country represents
the average of all CTVT prevalence estimates obtained from that country. The location of each response is indicated with a black dot. Countries
from which fewer than three responses were received are coloured in grey. Complete datasets are included in Additional file 6 and Additional file
7. Map was created using the maptools and ggmap packages, implemented in R. (B) Average reported CTVT prevalence by continent. The
number of responses estimating prevalence in each continent is shown above each bar.
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was present in remote indigenous communities, in-
cluding Indian reservations in Arizona and North
Dakota, as well as in Australian Aboriginal communi-
ties in the Northern Territory and Western Australia
(see Additional file 7). There was also geographical
variation in estimated CTVT prevalence in Europe; the
disease was reported to be absent except for occasional
imported cases in many countries of Northern and
Western Europe, but was estimated to be present at
less than ten percent prevalence in countries in South-
ern and Eastern Europe (see Additional file 7).Status of dogs with CTVT
We asked questionnaire respondents to report the most
likely gender and health status of animals with CTVT.
Despite previous suggestions that CTVT is more com-
mon in males [49,50] or females [51-55], responses to
the questionnaire indicated that there is no universal
gender bias for CTVT infection, with 144 respondents
reporting that CTVT was more common in males, 146
reporting that it was more common in females and 168
claiming that it was equally common in both sexes (chi-
squared test for no gender difference, p = 0.907) (Figure 3A).
The majority of respondents (459 out of 637) claimed that
Figure 3 Status of dogs with CTVT. (A) Gender of dogs infected with CTVT. Respondents were asked if they observed CTVT “more commonly
in males”, “more commonly in females” or “equally in males and females”. The numbers refer to the number of respondents choosing each
option. (B) Health condition of dogs infected with CTVT. Respondents were asked to report on the condition of the majority of CTVT-infected
dogs by selecting one of the four categories shown. The numbers refer to the number of respondents choosing each option. (C) Relationship
between spaying/neutering and CTVT prevalence. CTVT prevalence estimates from respondents who claimed that the majority of dogs in
their area were spayed/neutered (total of 120 respondents) or entire (total of 340 respondents) are coloured in red and green respectively.
Percentage of respondents refers to the proportion of respondents choosing each option.
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infected with parasites or otherwise diseased, thin or ema-
ciated, or carrying injuries or bite marks (Figure 3B). We
investigated the association of spaying/neutering with
CTVT presence by asking respondents whether the ma-
jority of dogs in their country are spayed/neutered or en-
tire. The responses showed that higher estimated CTVT
prevalence coincides with higher percentage of respon-
dents claiming that the majority of dogs are entire rather
than spayed or neutered (Figure 3C).
Despite previous reports of successful experimental trans-
mission of CTVT into wild canids, including wolves, coy-
otes and red foxes [3,30,56-58], no naturally occurring
CTVT case has been previously reported in a wild canid.
We further investigated this by asking all questionnaire re-
spondents if they had observed CTVT in a wild canid (see
Additional file 5). The responses did not reveal any con-
firmed reports of CTVT in wild canid populations.
Factors influencing CTVT prevalence
We next stratified countries based on income economy
(The World Bank, Country and Lending Groups [59]) and
found strikingly lower estimated prevalence of CTVT in
countries with high income economies, compared withthose with low, lower-middle and upper-middle income
economies, which had similar distributions of estimated
CTVT prevalence (Figure 4A). The proportion of coun-
tries with reported presence of free-roaming dogs was also
associated with income economy category (Figure 4B),
presenting the possibility that differences in presence of
free-roaming dogs may explain the link between CTVT
prevalence and national development status.
Additionally, we observed a weak negative correlation
between average reported CTVT prevalence and socio-
economic status, determined by Gross Domestic Product
(GDP) per capita value for each country (see Additional
file 8, Pearson’s correlation two tailed test between CTVT
prevalence and GDP values, r = −0.504, p = 4.52 × 10−5), to-
gether with a weak negative correlation between average re-
ported CTVT prevalence and distance from the equator, as
measured by distance from the equator to the capital city
of each country (see Additional file 8, Pearson’s correlation
two tailed test between CTVT prevalence and distance
from the equator, r = −0.416, p = 8.39 × 10−4). It is possible,
however, that these correlations, as well as a previously
identified correlation between CTVT prevalence and dis-
tance from the equator within the United States [60], may
be explained by the presence of free-roaming dogs.
Figure 4 Factors associated with CTVT prevalence. (A) Relationship between CTVT prevalence and socio-economic status defined as low/
lower-middle/upper-middle/high income economies (World Bank, Country and Lending Groups [59]). The size of the dots represents the number
of countries with estimated average CTVT prevalence within each interval. CTVT prevalence values represent the upper limit of each categorical
interval. (B) Relationship between socio-economic status defined by division into low/lower-middle/upper-middle/high income economies and
presence of free-roaming dogs, as reported by respondents to the questionnaire. “Percentage of countries” refers to the proportion of countries
within each income category in which the presence of free-roaming dogs was reported by the majority of respondents.
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CTVT metastasis has been previously noted in individ-
ual case reports [43,50,52,54,61-86]. We asked question-
naire respondents to estimate the proportion of CTVT
cases in which metastasis is observed. Of the six categor-
ical intervals available to respondents (“none”, “0-5%”,
“5-10%”, “10-15%”, “15-20%”, “more than 20%”), the ma-
jority of respondents estimated that metastasis occurs in
0–5 percent of CTVT cases (Figure 5A), consistent with
previously published estimates [1,49]. Additionally, we
recorded the most commonly observed sites of metasta-
sis reported by questionnaire respondents (Figure 5B).
Vincristine is known to be a very effective treatment
for CTVT [49,53,87-90]. We asked respondents to re-
port the type and effectiveness of treatments they typic-
ally administer for CTVT (Figure 5C). The majority of
respondents (373 out of 454 respondents, 82.2%) re-
ported that they use either vincristine alone or vincristine
in combination with surgery, doxorubicine or radiother-
apy. A proportion of respondents (10.9%, 50) reported
that they used surgery alone or other non-vincristine
treatments (4%, 18). Thirteen (2.9%) respondents stated
that the only option is euthanasia. Those who used vin-
cristine treatment for CTVT reported that 80 to 100 per-
cent of tumours usually went into complete remission
after treatment (Figure 5D), however the number of vin-
cristine doses claimed to be required for complete remis-
sion varied between respondents. This contrasted with the
poor reported effectiveness of surgery alone or other non-
vincristine treatments (Figure 5D).
Discussion
This survey of current and historical CTVT distribution
patterns confirms that CTVT was and remains a very
common canine infectious disease throughout the world.
The global CTVT prevalence data reported in this studyare individual estimates of local CTVT prevalence and
are thus subject to errors introduced by variation in
methodologies used by respondents to estimate preva-
lence (see Methods). Difficulties in prevalence estimation
may have been further confounded by a combination of
absent, inconsistent or incomplete record keeping, per-
sonal biases as well as systematic biases introduced
where the sampling population was not representative of
the population as a whole. Furthermore, variation in
CTVT prevalence due to seasonal, demographic or local
geographical factors may not have been captured by our
approach. In order to minimise the effects of estimate
biases on our analysis, we only included data from coun-
tries from which we received at least three responses in
Figure 2A and Figure 4. Despite the limitations associ-
ated with estimating global CTVT prevalence, our large
sample size supports the conclusion that a strikingly
large proportion of the global dog population harbours
CTVT infection at a prevalence of between 0.5 and 10
percent. Future studies will be important to further val-
idate global variation in CTVT prevalence.
We have documented the decline and disappearance
of CTVT from the United Kingdom during the twenti-
eth century (Figure 6 and Additional file 3). The eradica-
tion of CTVT from the United Kingdom may be due to
the introduction of a series of dog management laws
throughout the nineteenth and twentieth centuries (Figure 6).
The Dogs Act, 1871 [91] imposed civil responsibility on dog
owners and stated that dogs must be “under proper control”
and “stray dogs may be detained and sold or destroyed”. This
was followed by the Dogs Act 1906 [92], amended in 1928
and 1938, which introduced a requirement to report stray
dogs to the police. It is striking that the eradication of
CTVT, once a common canine pathogen in the United
Kingdom (see Additional file 3), appears to have occurred as
an unintentional result of human intervention.
Figure 5 CTVT metastasis and treatment. (A) Estimated proportion of CTVT cases with metastasis. Number of responses refers to the number
of respondents choosing each option. (B) Sites of CTVT metastasis reported by respondents. The size of the arrow is proportional to the number
of respondents who reported observations of CTVT metastasis at this site. (C) CTVT treatments reported by respondents. Total number of
responses for this question was 454. (D) CTVT response to treatment. “Response to treatment” refers to the proportion of CTVT cases that
respondents estimated went into complete remission after the selected treatment. “Other” treatments included euthanasia, aloe vera treatment
and electrocautery, but do not include chemotherapy.
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tering in CTVT control was highlighted by a respondent
from Koh PhaNgan Island, Thailand, where breeding
control and sterilisation campaigns have almost eradi-
cated CTVT from the island since the commencement
of the sterilisation project in 2001. Several respondents,
however, when asked to comment on any unusual cases
of CTVT that they had seen, commented that they had
observed CTVT in dogs years after spay or neuter sur-
gery. This suggests that either the latent period for
CTVT development, which previous anecdotal reports
have suggested may last for weeks or months [2,55,93],
can sometimes last years, or, alternatively, that spaying
and neutering does not always protect dogs from CTVT.
Furthermore, non-coital modes of CTVT transmission,
including biting, licking or sniffing, may also contribute
to CTVT infection of spayed/neutered dogs [68,94-98].
Despite the widespread presence of CTVT in dog pop-
ulations worldwide, the results of our survey indicatethat its prevalence rarely rises above 10% (Figure 2). This
contrasts with epidemiological patterns observed for the
only other known naturally occurring transmissible can-
cer, the Tasmanian devil facial tumour disease (DFTD).
Prevalence of DFTD usually rises above 50% in affected
Tasmanian devil populations and the disease usually
triggers a rapid population decline (reviewed in [99]).
Given that the mixed mating system of dogs would pro-
mote widespread exposure to the disease [100], this
pattern suggests that only a proportion of the dog
population may be susceptible to CTVT at any one
time and, possibly, as one early report of CTVT pro-
posed, that “some animals are naturally refractory” to
infection [5]. Future studies of CTVT exposure and
susceptibility in free-roaming dog populations may re-
veal further insights into the biological basis of this in-
teresting observation.
Genetic studies indicate that the global spread of
CTVT has occurred relatively recently in the history of
Figure 6 Disappearance of CTVT from the United Kingdom during the twentieth century. Timeline showing the declining number of
historical reports of CTVT in the United Kingdom, coinciding with the introduction of dog laws. Data from the questionnaire (indicated with black
and yellow dots) were used to confirm current absence (except for occasional imported cases) of CTVT from the United Kingdom. See also
Additional file 3.
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Although we do not know the location in which CTVT
first emerged, our study has highlighted the remarkable
efficiency with which CTVT has colonised its global
host population. We obtained evidence for CTVT’s pres-
ence in some of the world’s most isolated communities and
islands, including the Solomon Islands, Samoa, American
Samoa, Fiji, Reunion, Mauritius and several islands in
Micronesia. In contrast, New Zealand is free of CTVT, likely
due to its rigorous import quarantine rules [101]. Together,
these findings highlight the mobility of dogs, which, along-
side humans, have travelled rapidly and extensively around
the globe.
This study has provided information on historical and
current CTVT global distribution and prevalence and
has illuminated a number of factors which may influence
CTVT prevalence, including presence of free-roaming
dogs, dog spay/neuter practices and enforcement of dog
control laws. In addition to providing insight into the
global spread of a unique type of pathogen, this study
may assist policy-makers and veterinarians in the devel-
opment of measures to more effectively control and re-
duce CTVT prevalence and prevent further spread of
the disease.
Conclusions
Our results provide a survey of the current global distri-
bution of CTVT, confirming that CTVT is endemic in
at least 90 countries worldwide. Additionally, our ana-
lysis highlighted factors that continue to modify CTVT’s
prevalence around the world; free-roaming dogs were
implicated as a reservoir for the disease and spaying and
neutering were associated with lower CTVT prevalence.
Our analysis also documents the disappearance of the
disease from the United Kingdom during the twentiethcentury, which may have been an unintentional result of
the introduction of dog control policies. In addition to
providing insights into the global spread of a unique ca-
nine infectious disease, this study may assist veterinar-
ians and policy-makers to develop measures to more
effectively control and reduce CTVT prevalence and
spread.
Methods
This study was approved by the Department of Veterinary
Medicine, University of Cambridge, Ethics and Welfare
Committee (reference number CR105). The questionnaire
used in this study is available in supplementary materials
(see Additional file 5). Potential participants were selected
with an internet-based search. The questionnaire was sent
by email to 1025 individuals and distributed at several vet-
erinary conferences. The questionnaire was also circulated
in several veterinary societies’ mailing lists and published
in veterinary periodicals, newsletters and on social media
sites. Of the 645 completed questionnaires received, nine
respondents provided information about more than one
country. Most of the respondents were private veterinar-
ians (415, 64.3%) or veterinarians working at veterinary
schools (143, 22.2%), but they also included other individ-
uals working at charitable organisations (50, 7.8%), gov-
ernment (16, 2.5%), pathology laboratories (13, 2.0%)
and research agencies (8, 1.2%). All of the respondents
completed the questionnaire within days or weeks of
receiving it. The questionnaire was made available in
English, Chinese, French, Portuguese, Spanish and Russian.
The estimated average CTVT prevalence for each coun-
try was determined using the average of the mid-point
values for each reported prevalence category received
from each country. Only countries with three or more re-
sponses were included in the analyses in Figures 2A and 4,
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Additional file 7. Previous studies indicated that CTVT
prevalence rarely rises above 20 percent (see Additional
file 4), therefore the prevalence categories available in the
questionnaire were “none”, “less than 0.5%”, “0.5-1%”,
“1-3%”, “3-5%”, “5-10%”, “10-20%” and “more than
20%”. The CTVT prevalence figures reported here were
estimated by respondents based on (1) an estimate of the
number of CTVT patients as a proportion of total canine
patients in general clinical practice; (2) an estimate of the
total number of CTVT diagnostic samples as a proportion
of the total number of canine diagnostic samples passing
through a pathology laboratory; (3) a personal estimate
based on previous veterinary experience and discussions
with veterinary colleagues; and (4) the total number of
CTVT cases in populations of dogs participating in
spay/neuter campaigns.
The World Atlas [102] was used to generate the list of
countries in Additional file 6, and Taiwan and Reunion
were added as separate countries. Data on the distance
from the equator and GDP values were obtained from
News Track India [103] and the International Monetary
Fund [104] respectively. Distance from the equator for
each country refers to the distance of the capital city
from the equator. Countries were classified as low in-
come, lower-middle income, upper-middle income and
high income economies based on the classification
scheme defined by the World Bank [59].Additional files
Additional file 1: Contemporary and historical reports of naturally
occurring CTVT cases in the published literature. Reports are ordered
by date. Multiple reports from the same publication are indicated on
separate lines. Only reports referring to primary naturally occurring CTVT
cases are included, while articles reporting only cases of experimentally
transplanted CTVT are excluded.
Additional file 2: Global distribution of published reports of CTVT.
Locations in which naturally occurring CTVT cases are reported in the
published literature are indicated on the map, classified by date of report.
Bibliographical information for each case is found in Additional file 1. The
two reports in Canada [5,105] were specified as imported cases from
abroad and are marked with *. Map was created using Adobe Illustrator.
Additional file 3: Historical reports confirming presence of CTVT in
the United Kingdom in the 19th and 20th centuries. The comments
were obtained from articles published between 1810 and 1969.
Additional file 4: Contemporary and historical reports providing a
numerical value for CTVT prevalence.
Additional file 5: Text version of CTVT questionnaire used in this
study.
Additional file 6: Summary of CTVT prevalence data by country.
Additional file 7: Worldwide CTVT distribution and prevalence. (A) Map
indicating CTVT prevalence estimated by each respondent. Each response is
represented by a single coloured dot. Map was created using Adobe Illustrator.
(B) Higher magnification map showing detailed distribution of CTVT prevalence
estimates in Europe. Map was created using Adobe Illustrator.
Additional file 8: Socio-economic and climatic factors associated
with CTVT prevalence. (A) Relationship between estimated CTVTprevalence and Gross Domestic Product (GDP) per capita values in US
dollars. Prevalence values displayed represent the higher limit of each
categorical interval. Each dot represents the average of three or more
estimated prevalence values received from that country. A line of best fit
is displayed (R2 = 0.2543). (B) Relationship between estimated CTVT
prevalence and geographical latitude displayed as distance from the
equator (in degrees of latitude) measured for the capital city of each
country. Prevalence values displayed represent the higher limit of each
categorical interval. Each dot represents the average of three or more
estimated prevalence values received from that country. A line of best fit
is displayed (R2 = 0.1727).
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